Finance

Beta
Lists
ZNTL:NASDAQ
Zentalis Pharmaceuticals Inc
$3.68
+0.27%
(+0.0100) 1D
$3.50
-4.89% (-0.18)
After hours
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZNTL...
Open
$3.60
High
$3.80
Low
$3.60
Mkt. cap
261.97M
Avg. vol.
932.39K
Volume
0.00
52-wk high
$6.95
52-wk low
$1.13
EPS
-$1.74
Beta
1.96
Shares outstanding
71.19M
No. of employees
106
Open
$3.60
High
$3.80
Low
$3.60
Mkt. cap
261.97M
Avg. vol.
932.39K
Volume
0.00
52-wk high
$6.95
52-wk low
$1.13
EPS
-$1.74
Beta
1.96
Shares outstanding
71.19M
No. of employees
106
News stories
From sources across the web
About Zentalis Pharmaceuticals Inc
CEO-
Employees106
Founded2014
Headquarters-
SectorBiotechnology
Websitezentalis.com
Analyst Ratings
Based on 7 analysts giving stock ratings to ZNTL in the past 3 months
Buy
Buy
4
Hold
3
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ZNTL in the last 3 months.
Highest
Current $3.68
$10.00 (+171.74%)
Average
$7.00 (+90.22%)
Lowest
$4.00 (+8.70%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Jay Olson
Oppenheimer
Buy
Initiated
$9.00
+144.6%
06/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$10.00
+171.7%
05/26/2026
Unknown Analyst
Wedbush
Hold
Maintained
$4.00
+8.7%
05/13/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$4.00
+8.7%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$9.00
+144.6%
05/13/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$5.00
+35.9%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$10.00
+171.7%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.61M
22.95M
30.69M
28.72M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.30M
10.78M
3.77M
9.14M
Operating expense
34.91M
33.73M
34.46M
37.86M
Total operating expenses
34.91M
33.73M
34.46M
37.86M
Operating income
-34.91M
-33.73M
-34.46M
-37.86M
Other non operating income
-
7.04M
-11.85M
-
EBT including unusual items
-26.87M
-26.69M
-34.77M
-35.23M
EBT excluding unusual items
-25.72M
-26.69M
-34.12M
-35.23M
Income tax expense
-
-
442.00K
120.00K
Effective tax rate
-
-
-1.27%
-0.34%
Other operating expenses
-
-
-
-
Net income
-26.87M
-26.69M
-35.22M
-35.35M
Net profit margin
-
-
-
-
Earnings per share
-0.37
-0.37
-0.49
-0.50
Interest and investment income
9.18M
-
12.19M
2.62M
Interest expense
-
-
-
-
Net interest expenses
9.18M
-
12.19M
2.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.75M
-33.57M
-34.30M
-37.70M
Gain or loss from assets sale
-531.00K
-103.00K
-26.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer